Hepatic Cell News

Hepatic Cell News is an online resource covering the top research on hepatocytes and liver diseases.

Liver Organoids: From Disease Modeling to Regenerative Medicine

August 19, 2026

[Cell Proliferation] The authors systematically summarize current fabrication strategies, disease-modeling utilities and regenerative potentials of liver organoids, alongside the major challenges and future directions.

Scalable Synthetic Peptide Hydrogel Enables Self-Organized Luminal Cavity Architecture Within hiPSC 3D Colonies Supporting Functional Hepatocyte Differentiation

August 14, 2026

[Bioactive Materials] Scientists reported a scalable synthetic peptide hydrogel platform that enables hiPSCs to self-organize into long-term, proliferative luminal cavity architectures within 3D colonies.

Leveraging IGF Signaling to Improve the Spatial Organization and Regenerative Potential of iPSC-Derived Vascularized Liver Organoids

August 14, 2026

[Science Advances] Researchers developed vascularized liver organoids by integrating hiPSC–derived hepatoblasts and endothelial cells into decellularized scaffolds functionalized with an anti-CD31 aptamer–based vascular coating agent.

The Circadian Clock Controls Hepatic Stellate Cell Activation via a BMAL1/CK1ε/REV-ERBα/Transgelin Signaling Pathway

August 14, 2026

[Proceedings of the National Academy of Sciences of the United States of America] Investigators showed that although the liver clock is generally maintained during human disease progression from a fatty liver to fibrosis, changes in circadian gene amplitude occur in people with obesity.

SLC25A1-Targeted Gene Therapy Attenuates Liver Fibrosis through NEDD4-Mediated Ubiquitination and Degradation of PPARγ

August 14, 2026

[Pharmacological Research] Scientists investigated the role of SLC25A1 in regulating lipid droplet homeostasis during hepatic stellate cell activation and evaluated its therapeutic potential in experimental liver fibrosis.

CSTF2-Mediated 3′UTR Shortening Drives Oncogenic Activation of GPC3 in Hepatocellular Carcinoma

August 14, 2026

[Oncogene] The authors profiled mRNA length alterations in multistage human hepatocellular carcinoma transcriptome datasets and investigated their functional consequences.

Lower Glucagon Response and Attenuated Hepatic Glucagon Signaling in MASLD

August 14, 2026

[Diabetes & Metabolism] Researchers investigated the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) severity and plasma glucagon dynamics, and evaluate hepatic glucagon signaling using human liver tissue.

Dynamic Responses of Cancer-Associated Fibroblasts to Therapy in Primary Liver Cancer

August 14, 2026

[Cancer Letters] Scientists summarize cancer-associated fibroblast subpopulations, including their markers and functions, in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

$1 Million Grant Fuels Research on Precise Cancer Radiation

August 14, 2026

[University of Missouri School of Medicine] Researchers from the University of Missouri School of Medicine recently received a $1 million grant from the National Institutes of Health to study the latest technology in cancer research.

Pilatus Biosciences Announces Hong Kong Clinical Trial Application Approval for PLT012 and Expansion into Hong Kong

July 31, 2026

[Pilatus Biosciences, Inc.] Pilatus Biosciences, Inc., announced that the Hong Kong Department of Health has granted the Certificate for Clinical Trial / Medicinal Test for lead investigational therapy, PLT012 in patients with advanced solid tumors.

P21-Activated Kinase 4 Drives Hepatic Stellate Cell Activation and Liver Fibrosis through the Phosphorylation of YAP at T428

July 31, 2026

[Signal Transduction and Targeted Therapy] Scientists demonstrated the role of p21-activated kinase 4, an emerging therapeutic target, in the activating phosphorylation of Yes-associated protein (YAP) and subsequent hepatic stellate cell activation.

H3K18 Lactylation Drives CD8+ T Cell Exclusion and Anti-PD-1 Resistance in Hepatocellular Carcinoma

July 31, 2026

[Cell Reports] Investigators identified H3 lysine 9 lactylation (H3K9la) as a potential key target for driving resistance to anti-PD-1 immunotherapy in HCC.

The publications featured in Hepatic Cell News are expertly selected by our in-house editorial team from high impact, peer-reviewed academic journals. We cover areas including the culturing and characterization of hepatocytes, liver stem cells, and the pathogenesis of conditions such as liver cirrhosis and hepatocellular carcinoma. Additionally, we provide the latest updates on broader news, upcoming events, and job postings to keep the global liver research community connected!